Benzinga · Aug 24, 2026
Guardant Health Hit With Ongoing Royalties Over Duplex Sequencing Tech
Guardant Health must pay TwinStrand Biosciences and the University of Washington over $245 million after a court finalized a patent dispute.
GH
NASDAQ · GH
Guardant Health, Inc.
Healthcare · Medical - Diagnostics & Research
$164.41
Up+$5.39 (+3.39%)
Updated Sep 2, 2026, 12:47 PM
SID Score
6.5/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 12.58B
- P/E ratio
- -31.72
- Dividend yield
- 0.00%
- 52-week range
- $53.40 – $176.58
- Volume
- 2.44M
- Avg. volume
- 2.66M
Price performance
GH price history
1M range · 0 trading sessions · Daily adjusted prices
GH does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest GH news
The latest Smart Investors Daily articles mentioning GH.
Stock researchCompany · Overview
GH research
Overview
Company profile and research snapshot.
Company profile
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $93.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | Piper Sandler | Overweight | — |
| Aug 4, 2026 | Stephens & Co. | Overweight | — |
| Aug 4, 2026 | Morgan Stanley | Overweight | — |
| Aug 3, 2026 | Stifel | Buy | — |
| Jul 31, 2026 | TD Cowen | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 12, 2026
Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Guardant Health, Inc. (GH) Canaccord Genuity's 46th Annual Growth Conference August 12, 2026 3:00 PM EDTCompany ParticipantsHelmy Eltoukhy - Co-Founder,...
Benzinga · Aug 4, 2026
Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $193
Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $135 to $193.
Benzinga · Aug 4, 2026
Stephens & Co. Maintains Overweight on Guardant Health, Raises Price Target to $195
Stephens & Co. analyst Mason Carrico maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $170 to $195.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
